FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Trachtenberg Eric (Last) (First) (Middle) C/O KALA PHARMACEUTICALS, INC. 490 ARSENAL WAY, SUITE 120						Issuer Name and Ticker or Trading Symbol Kala Pharmaceuticals, Inc. [KALA] Date of Earliest Transaction (Month/Day/Year) 01/04/2021								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title Other (specify below) See Remarks					vner	
(Street) WATERTOWN MA 02472 (City) (State) (Zip)							4. If Amendment, Date of Original Filed (Month/Day/Year)							Line)	X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transac (Month/Date					saction	action 2A. Deemed Execution Date,		3. Transa Code (ction	4. Securities Acquired (A Disposed Of (D) (Instr. 3,		ed (A)	or 5. Amount Securities Beneficial Owned Fo		nt of 6. Ow Form (D) or ollowing (I) (In		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
Common Stock ⁽¹⁾ 01/0				4/202	1/2021		Code	v	Amount 22,66	(A) or (D) Prid		ice \$0	(Instr. 3 a	Transaction(s) (Instr. 3 and 4)		D	(Instr. 4)			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	if any		4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title an of Securit Underlyin Derivative (Instr. 3 an	ies g Secur		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amor or Numl of Share	ber						
Stock Option (right to buy)	\$6.86	01/04/2021			A		90,667		(3)	C	01/03/2031	Common Stock	90,6	667	\$0	90,66	7	D		

Explanation of Responses:

- 1. Grant of restricted stock units ("RSUs") under the Issuer's 2017 Equity Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock. Subject to the reporting person's continued employment with Issuer, the RSUs will vest as to 1/3 of the shares underlying the RSUs on January 4, 2022, as to 1/3 of the shares underlying the RSUs on January 4, 2023 and as to the final 1/3 of shares underlying the RSUs on January 4, 2024.
- 2. Includes 99,666 unvested RSUs
- 3. This option was granted on January 4, 2021 and vests with respect to 1/48th of the shares underlying the option at the end of each successive one-month period thereafter.

General Counsel, Chief Compliance Officer and Secretary

/s/ Eric Trachtenberg 01/05/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.